7:06AM ISIS Pharm earns $2 mln from GSK for the advancement of ISIS-TTR Rx (ISIS) 27.79 : Co announced that it has earned a $2 mln milestone payment from GlaxoSmithKline (GSK) related to the advancement of the ongoing Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). Isis has earned $20 million in upfront and milestone payments prior to first patient dosed in the ongoing Phase 2/3 study. The $2 million milestone payment announced today is the first milestone of the $50 million in milestone payments Isis is eligible to earn as the Phase 2/3 study progresses. In addition, if GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
Market Data 
Markets 
AI
